Skip to main content

Hematology/Oncology Trainee Experiences During the COVID-19 Pandemic and Beyond With Samuel Kareff, MD, MPH, and Ana Velazquez Mañana, MD

This Oncology Data Advisor® Fellows Forum Interview features Dr. Samuel Kareff, Hematology/Oncology Chief Fellow at the University of Miami Sylvester Comprehensive Cancer Center, in discussion with Dr. Ana Velazquez Mañana, an Assistant Professor of Medicine in the Division of Hematology-Oncology at the University of California, San Francisco (UCSF), regarding the unique challenges faced by hematology/oncology trainees during the COVID-19 pandemic. Dr. Velazquez Mañana outlines the impacts on clinical training, research, and career development, as well as the positive changes that have been incorporated into the landscape for hematology/oncology trainees.  

Continue reading

Developing Training on Medical Cannabis Education for Oncology Fellows With Deepa Rangachari, MD

At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor® sat down with Dr. Deepa Rangachari, Director of Hematology/Oncology Graduate Medical Education at Beth Israel Deaconess Medical Center, to learn more about her presentation on her team's development of a novel curriculum to train Hematology/Oncology Fellows in the use of medical cannabis for their patients. 

Continue reading

Introducing the Oncology Data Advisor® Fellows Forum: A Valuable Resource for Hematology/Oncology Fellows With Samuel Kareff, MD, MPH

Oncology Data Advisor® is excited to announce the launch of the Fellows Forum, a new resource featuring expert perspectives geared toward Hematology/Oncology Fellows. In this interview, Dr. Samuel Kareff, Chief Hematology/Oncology Fellow at the University of Miami's Sylvester Cancer Center, shares the educational topics that he is looking forward to sharing his insights on as a Fellows Forum member, including tips for fellowship application, specialty pros and cons, research advances, and collaborations with policymakers and patient advocacy groups.  

Continue reading